Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Endocrinol Invest ; 31(10): 900-4, 2008 Oct.
Article in English | MEDLINE | ID: mdl-19092296

ABSTRACT

HRPT2 and parafibromin studies improved the diagnostic accuracy in two patients with primary hyperparathyroidism (PHPT) referred to us after surgery, in whom the clinical data were at variance with the pathological diagnosis of adenoma and carcinoma, respectively. Patients were referred to us after parathyroidectomy. Patient #1 had had a 1.5-cm tumor easily removed with a histological diagnosis of parathyroid carcinoma and normocalcemia for 2 years. Re-examination of the histology showed no cardinal signs of parathyroid cancer. Patient #2, with severe PHPT, had had the removal of a 3.5-cm tumor described histologically as adenoma. Ten years later PHPT recurred and persisted despite removal of two mildly enlarged parathyroid glands that were histologically normal. Re-review of the initial histology showed a trabecular pattern, fibrous bands, and atypical mitoses, suggesting an atypical adenoma. Because of the suspicion that case #1 could be an atypical adenoma and case #2 a carcinoma further molecular studies were performed. No HRPT2 and parafibromin abnormalities were identified in patient #1, strongly indicating a benign lesion. In patient #2, an HRPT2 germline mutation was found (E115X in exon 4) and associated with no parafibromin staining. These data, together with the clinical features, supported the suspicion of a parathyroid carcinoma that was confirmed by histological examination of further slides of the tumor, showing capsular and vascular invasion. A lung 1.5-cm nodule detected by computed tomography was excised. Histology showed a metastasis of parathyroid carcinoma. HRPT2 gene studies improved the diagnostic accuracy in 2 parathyroid tumors that are of uncertain type.


Subject(s)
Hyperparathyroidism, Primary/genetics , Parathyroid Neoplasms/genetics , Tumor Suppressor Proteins/genetics , Adenoma/genetics , Adenoma/pathology , Carcinoma/genetics , Carcinoma/pathology , Humans , Hyperparathyroidism, Primary/pathology , Male , Middle Aged , Parathyroid Neoplasms/pathology
2.
Endocr Relat Cancer ; 14(2): 493-9, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17639062

ABSTRACT

Early onset of primary hyperparathyroidism (PHPT) and multiglandular involvement suggest a familial form in which germline mutation of a PHPT-related gene(s) and a somatic event at the same locus can be often demonstrated. We investigated the involvement of multiple endocrine neoplasia type 1 (MEN1) and HRPT2 genes in a 39-year-old man with recurrent PHPT. PHPT was firstly diagnosed at the age of 21 and the patient had two recurrences separated by extended periods of normocalcemia. This unusual history prompted us to investigate other family members and study the MEN1 and HRPT2 genes. An HRPT2 germline missense mutation in exon 3 (R91P) was found in the index case, which was associated with different HRPT2 somatic alterations in each of the three examined parathyroid tumors. These findings are consistent with Knudson's 'two hit' concept of biallelic inactivation of classical tumor suppressor genes. Screening of 15 asymptomatic relatives was negative for the R91P germline mutation. All the three abnormal parathyroid specimens showed cystic features at histology and were negative for parafibromin immunostaining. In one specimen, diffuse parafibromin staining was evident in a rim of normal parathyroid tissue surrounding the adenomatous lesion. Our study shows that different somatic genetic events at the HRPT2 locus are responsible for the asynchronous occurrence of multiple adenomas in a patient carrying an HRPT2 germline mutation. The finding of diffuse parafibromin staining in a rim of normal parathyroid tissue, but not in the contiguous adenomatous lesion, reinforces the concept that loss of parafibromin expression is responsible for the development of parathyroid tumors in this setting.


Subject(s)
Hyperparathyroidism, Primary/pathology , Parathyroid Glands/pathology , Tumor Suppressor Proteins/genetics , Adult , DNA Mutational Analysis , Germ-Line Mutation , Humans , Loss of Heterozygosity , Male , Mutation, Missense , Parathyroid Glands/chemistry , Proto-Oncogene Proteins/genetics , Recurrence , Tumor Suppressor Proteins/analysis
3.
J Endocrinol Invest ; 28(3): 280-4, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15952415

ABSTRACT

We report a case of acute hepatitis of autoimmune origin which occurred in a 43-yr-old woman during iv glucocorticoid (GC) pulse therapy for Graves' ophthalmopathy (GO). Prior to therapy, liver function tests were normal with no previous history of liver disorders or conditions predisposing to GC-associated liver damage. After the administration of a 4.7-g cumulative dose of methylprednisolone acetate, there was a marked increase of liver enzymes, prompting immediate discontinuation of iv GC. Nevertheless, liver enzymes increased further, reaching a peak 45 days later, with values 30- to 50-fold greater than those prior to therapy, associated with evidence of impaired liver function. Liver biopsy showed a marked lymphocytic infiltration, likely indicating an autoimmune hepatitis. Based on the assumption that following GC-induced immune suppression, autoimmune hepatitis might have been precipitated by sudden re-activation of the immune system during interpulse periods, we treated the patient with im and then oral GC, in order to re-induce immune suppression. Within three days from re-institution of GC therapy, there was a marked reduction of liver enzymes and amelioration of liver function. Complete normalization was achieved two months later, while the patient was still receiving a low maintenance dose of oral prednisone.


Subject(s)
Glucocorticoids/adverse effects , Glucocorticoids/therapeutic use , Graves Disease/complications , Graves Disease/drug therapy , Hepatitis, Autoimmune/etiology , Adult , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/therapeutic use , Body Mass Index , Female , Graves Disease/radiotherapy , Humans , Liver/enzymology , Liver/pathology , Liver Function Tests , Lymphocytes/physiology , Methylprednisolone/adverse effects , Methylprednisolone/therapeutic use , Prednisone/therapeutic use
4.
J Endocrinol Invest ; 28(10 Suppl): 43-7, 2005.
Article in English | MEDLINE | ID: mdl-16550722

ABSTRACT

Recent studies have suggested a possible role of T-cells and tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of bone loss which occurs in systemic inflammatory diseases. The relevance of T-cells activity in bone loss due to estrogen deficiency has been investigated in recent years by Dr. Pacifici's group. They have shown that the increased presence of TNF-alpha producing T-cells is essential for the changes in bone metabolism during estrogen deficiency. Lack of estrogen increases interferon-y (INF-y) production by helper T-cells, which through complex class II an increased expression of major histocompatibility complex class II (MCHII) on antigen presenting cells, enhances the activation and proliferation of TNF-alpha producing T-cells. The protective role of estrogen on bone loss is mediated by type beta transforming growth factor (TGF-beta), which blocks T-cell activation and T-cell TNF-alpha production by repressing antigen presentation.


Subject(s)
Autoimmune Diseases/immunology , Osteoporosis, Postmenopausal/immunology , T-Lymphocytes/immunology , Aged , Aged, 80 and over , Animals , Autoimmune Diseases/physiopathology , Bone and Bones/metabolism , Disease Models, Animal , Estrogens/deficiency , Estrogens/physiology , Female , Histocompatibility Antigens Class II/immunology , Histocompatibility Antigens Class II/physiology , Humans , Lymphocyte Activation , Major Histocompatibility Complex , Middle Aged , Osteoporosis, Postmenopausal/physiopathology , T-Lymphocytes/physiology , Transforming Growth Factor beta/metabolism , Tumor Necrosis Factor-alpha/metabolism
5.
J Endocrinol Invest ; 27(7): 687-90, 2004.
Article in English | MEDLINE | ID: mdl-15505996

ABSTRACT

We report a 39-yr-old woman with spontaneous short-term remission of primary hyperparathyroidism (PHPT). She was referred to our Department for PHPT with bilateral kidney stones diagnosed elsewhere; at the time of our observation she had developed anterior neck pain associated with swelling and tenderness. Biochemical data (serum ionized calcium and PTH) suggested a remission of the PHPT. The local symptoms gradually improved and disappeared over the next several days without therapy. Serum ionized calcium and PTH levels remained normal for up to 11 months. Subsequently, the patient had a recurrence of PHPT with mild hypercalcemia and elevated PTH levels. The patient underwent surgery and pathological examination revealing a 1.0 x 1.2 cm parathyroid adenoma with areas of necrosis with hemosiderinladen macrophages. In conclusion, we describe a case of spontaneous short-term remission of PHPT due to infarction of parathyroid adenoma.


Subject(s)
Adenoma/blood supply , Adenoma/complications , Hyperparathyroidism/pathology , Infarction , Parathyroid Neoplasms/blood supply , Parathyroid Neoplasms/complications , Adenoma/pathology , Adult , Female , Humans , Neck/pathology , Pain/etiology , Parathyroid Neoplasms/pathology , Remission, Spontaneous
6.
J Endocrinol Invest ; 25(6): 508-12, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12109621

ABSTRACT

Loss of heterozygosity (LOH) in the MEN1 region on chromosome 11q13 and MEN1 gene mutations have been found in a subset of sporadic parathyroid tumors. The question of whether these genetic abnormalities in the parathyroid tumors might influence the clinical and biochemical characteristics of primary hyperparathyroidism (PHPT) remains to be elucidated. The aim of the present study was to correlate the presence of MEN1 gene alterations in PHPT tumors with the clinical phenotype. Using microsatellite analysis for LOH at 11q13 and DNA sequencing of the coding exons, the MEN1 gene was studied in 38 parathyroid tumors of patients with sporadic PHPT. Fourteen tumors showed LOH at 11q13, and mutations of MEN1 gene were detected in 7 cases. The clinical and biochemical characteristics of patients were unrelated to the presence or absence of LOH and/or MEN1 gene mutations. In conclusion, MEN1 gene alterations are rather common in sporadic PHPT and their presence does not correlate with the clinical manifestations of the disease.


Subject(s)
Adenoma/genetics , Hyperparathyroidism/genetics , Multiple Endocrine Neoplasia Type 1/genetics , Parathyroid Neoplasms/genetics , Phenotype , Chromosomes, Human, Pair 11 , DNA Mutational Analysis , Female , Humans , Loss of Heterozygosity , Male , Microsatellite Repeats , Middle Aged , Mutation , Sequence Analysis, DNA
7.
Eur J Endocrinol ; 146(6): 783-8, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12039698

ABSTRACT

OBJECTIVE: The traditional surgical approach for patients with primary hyperparathyroidism (PHPT) consists of the identification of at least four glands and in the removal of all hyperfunctioning parathyroid tissue. DESIGN: To evaluate whether intraoperative parathyroid hormone (PTH) monitoring will allow a more limited surgical procedure by confirming complete removal of all hyperfunctioning tissue. METHODS: Plasma samples were obtained from 206 consecutive patients with sporadic PHPT before skin incision, during manipulation of a suspected adenoma, and 5 min (T-5) and 10 min after removal of abnormal parathyroid tissue. PTH was measured by a quick immunochemiluminescent assay (QPTH). The operative success was defined by a decrease of PTH greater than 50% of the highest pre-excision value. RESULTS: A >50% decrease of PTH occurred in 203 patients and was evident at T-5 in the majority of cases. All but three had normal serum calcium the day after surgery and afterwards. PTH concentration did not show a >50% decrease in the remaining three cases after completion of surgery. One patients had negative neck exploration and remained hypercalcemic; the other two had normal serum calcium at follow-up. Thus, the intraoperative QPTH correctly predicted the outcome of surgery in 201 patients (97.5%) (200 true positive and 1 true negative), and provided three false positive and two false negative results. CONCLUSIONS: The intraoperative QPTH measurement represents a useful tool to assist the surgeon during parathyroidectomy. It indicates whether all hyperfunctioning parathyroid tissue has been removed, limiting the procedure to a unilateral neck exploration in most cases.


Subject(s)
Hyperparathyroidism/blood , Hyperparathyroidism/surgery , Parathyroid Hormone/blood , Parathyroidectomy , Adult , Aged , Aged, 80 and over , Female , Humans , Immunohistochemistry , Luminescent Measurements , Male , Middle Aged , Monitoring, Intraoperative
SELECTION OF CITATIONS
SEARCH DETAIL
...